Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2477
Structure:
Synonyms:
36505-84-7
5-25-10-00059 (Beilstein Handbook Reference)
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
8-Azaspiro(4,5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)piperizinyl)butyl)-
8-Azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-
8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-
8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dion
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
AB00053432
Ansial
BAS 00928841
Biomol-NT_000108
BPBio1_000547
BPBio1_001403
BRN 0964904
BSPBio_000497
Buspar
Buspirona
Buspirona [INN-Spanish]
Buspirone
Buspirone (INN)
Buspirone HCL
Buspirone hydrochloride
Buspirone [INN:BAN]
Buspirone-MDTS
Buspironum
Buspironum [INN-Latin]
C06861
C13H21NO2.C9H14N4
CAS-33386-08-2
CHEBI:3223
CID2477
D07593
DB00490
DivK1c_000921
EINECS 253-072-2
Gen-Buspirone
Gen-Buspirone (TN)
IDI1_000921
KBio1_000921
KBio2_002236
KBio2_004804
KBio2_007372
KBioSS_002236
Lopac-B-7148
Lopac0_000223
LS-22723
MJ-9022-1
N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide
NCGC00015162-01
NCGC00016820-01
NCGC00024905-01
NCGC00024905-02
NCGC00024905-03
NINDS_000921
Prestwick0_000369
Prestwick1_000369
Prestwick2_000369
Prestwick3_000369
SPBio_002418
Spectrum_001756
STOCK1S-11244
Tocris-0962
ATC-Codes:
Side-Effects:
Side-EffectFrequency
insomnia1.0
paresthesia1.0
weakness1.0
numbness1.0
nightmares1.0
nervousness1.0
nausea1.0
nasal congestion1.0
fatigue1.0
sweating1.0
tachycardia1.0
blurred vision1.0
sore throat1.0
muscle aches1.0
lightheadedness1.0
dry mouth1.0
vomiting1.0
tremor1.0
tinnitus1.0
skin rash1.0
chest pain1.0
headache1.0
drowsiness1.0
constipation1.0
diarrhea1.0
confusion1.0
dizziness0.667
anorexia0.01
weight loss0.01
chills0.01
hypersalivation0.01
spasms0.01
arthralgia0.01
malaise0.01
menstrual irregularity0.01
dry skin0.01
blisters0.01
rectal bleeding0.01
shortness of breath0.01
hypertension0.01
hypotension0.01
weight gain0.01
fever0.01
flatulence0.01
urinary frequency0.01
irritable colon0.01
hair loss0.01
easy bruising0.01
breakthrough bleeding0.01
flushing0.01
muscle cramps0.01
edema0.009999999
pruritus0.009999999
seizures0.0082
hallucinations0.0082
syncope0.0082
alcohol abuse0.0010
photophobia0.0010
restlessness0.0010
amenorrhea0.0010
cerebrovascular accident0.0010
cardiomyopathy0.0010
acne0.0010
parkinsonism0.0010
allergic reactions0.0010
galactorrhea0.0010
bradycardia0.0010
angioedema0.0010
stiff neck0.0010
urinary retention0.0010
enuresis0.0010
myocardial infarction0.0010
serotonin syndrome0.0010
leukopenia0.0010
flu0.0010
hiccups0.0010
congestive heart failure0.0010
eosinophilia0.0010
epistaxis0.0010
ecchymosis0.0010
dyskinesias0.0010
nocturia0.0010
ataxias0.0010
impotence0.0010
vertigo0.0010
urticaria0.0010
erythema0.0010
cold intolerance0.0010
thrombocytopenia0.0010
restless leg syndrome0.0010
psychosis0.0010
thinking abnormal0
excitement0
feeling high0
depersonalization0
emotional lability0
euphoria0
dysphoria0
stupor0
hemorrhage0
palpitations0
urinary hesitancy0
pelvic inflammatory disease0
dysuria0
conjunctivitis0
aphonia0
eye pain0
muscle weakness0
anger0

Target

show target details
Uniprot ID:CP2D6_HUMAN
Synonyms:
CYPIID6
Cytochrome P450 2D6
Debrisoquine 4-hydroxylase
P450-DB1
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2F9Q
Structure:
2F9Q

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----

References:

15185539
15640381
Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.. Mingshe Zhu; Weiping Zhao; Humberto Jimenez; Donglu Zhang; Suresh Yeola; Renke Dai; Nimish Vachharajani; James Mitroka (2005) Drug metabolism and disposition: the biological fate of chemicals display abstract
This study was carried out to determine the metabolic pathways of buspirone and cytochrome P450 (P450) isoform(s) responsible for buspirone metabolism in human liver microsomes (HLMs). Buspirone mainly underwent N-dealkylation to 1-pyrimidinylpiperazine (1-PP), N-oxidation on the piperazine ring to buspirone N-oxide (Bu N-oxide), and hydroxylation to 3'-hydroxybuspirone (3'-OH-Bu), 5-hydroxybuspirone (5-OH-Bu), and 6'-hydroxybuspirone (6'-OH-Bu) in HLMs. The apparent K(m) values for buspirone metabolite formation in pooled HLMs were 8.7 (1-PP), 34.0 (Bu N-oxide), 4.3 (3'-OH-Bu), 11.4/514 (5-OH-Bu), and 8.8 microM (6'-OH-Bu). CYP3A inhibitor ketoconazole (1 microM) completely inhibited the formation of all major metabolites in HLMs (0-16% of control), whereas the chemical inhibitor selective to other P450 isoforms had little or no inhibitory effect. Recombinant CYP3A4, CYP3A5, and CYP2D6 exhibited buspirone oxidation activities among nine P450 isoforms tested. The overall metabolism rate of 5 microM buspirone by CYP3A4 was 18-fold greater than that by CYP2D6 and 35-fold greater than that by CYP3A5. In a panel of HLMs from 16 donors, buspirone metabolism correlated well CYP3A activity (r2 = 0.85-0.96, rho < 0.0005), but not the activities of other P450 isoforms. The metabolism rates of buspirone in CYP2D6 poor-metabolizer genotype HLMs were comparable to those in pooled HLMs. Taken together, these data suggest that CYP3A, mostly likely CYP3A4, is primarily responsible for the metabolism of buspirone in HLMs.